Healthcare
ABL Diagnostics – Approval of Dividend Distribution for Fiscal Year 2025
WOIPPY, France, July 02, 2026--Regulatory News: At the Annual General Meeting of ABL Diagnostics (Paris:ABLD) held on Tuesday, June 30, 2026, at 11:00 a.m., shareholders approved all resolutions submitted for their vote, including the payment of a dividend of €0.11 per share for the 2025 fiscal year (compared with €0.05 per share for the 2024 fiscal year), reflecting the Company's improved results and strong financial position.
About this update from Abl Diagnostics Sa
WOIPPY, France, July 02, 2026--(BUSINESS WIRE)--Regulatory News: At the Annual General Meeting of ABL Diagnostics (Paris:ABLD) held on Tuesday, June 30, 2026, at 11:00 a.m., shareholders approved all resolutions submitted for their vote, including the payment of a dividend of €0.11 per share for the 2025 fiscal year (compared with €0.05 per share for the 2024 fiscal year), reflecting the Company's improved results and strong financial position. The dividend will be ex-dividend on July 3, 2026, and will be paid on July 7, 2026. About ABL Diagnostics (ABLD) ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers: ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion. ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. An expanding portfolio of microbiology products: Integrated Solutions ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology. View source version on businesswire.com: https://www.businesswire.com/news/home/20260702954947/en/ Contacts ABL Diagnostics SA Société anonyme au capital de 1 611 465,60 eurosHeadquarters : 72C route de Thionville - 57140 WOIPPY552 064 933 R.C.S. METZ Tel : +33 (0)7 83 64 68 50Email : [email protected] https://www.abldiagnostics.com/
View stock analysis, news, and events for Abl Diagnostics Sa